MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Period	Net Profit Margin
2015-12-31	N/A
2016-12-31	N/A
2017-12-31	N/A
2018-12-31	N/A
2019-12-31	N/A
2020-12-31	N/A
2021-12-31	-251.00%
2022-12-31	N/A
2023-12-31	-857.15%
2024-12-31	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MNOV	$1.45	+2.11%	0.02M
3
4
5

MediciNova Inc. (MNOV) Profit Margin

Profit Margin Data

Get MediciNova Inc. Data in Excel

More MNOV Financial Data